Research programme: malignant melanoma vaccines - Affinivax
Latest Information Update: 28 Mar 2025
At a glance
- Originator Affinivax
- Class Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunotherapies; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Malignant-melanoma in USA
- 16 Aug 2022 Affinivax has been acquired by GlaxoSmithKline
- 17 Feb 2021 Early research in Malignant melanoma in USA, prior to February 2021 (Affinivax pipeline, February 2021)